BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21717519)

  • 1. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
    Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
    Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
    Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
    Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.
    Iacobone M; Barzon L; Porzionato A; Masi G; Macchi V; Marino F; Viel G; Favia G
    Surgery; 2007 Dec; 142(6):984-91; discussion 984-91. PubMed ID: 18063086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
    Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
    Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.
    Corbetta S; Vaira V; Guarnieri V; Scillitani A; Eller-Vainicher C; Ferrero S; Vicentini L; Chiodini I; Bisceglia M; Beck-Peccoz P; Bosari S; Spada A
    Endocr Relat Cancer; 2010 Mar; 17(1):135-46. PubMed ID: 19926710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of nm23 antimetastatic gene product in parathyroid hyperplasia, adenoma and carcinoma. An immunohistological assessment.
    Al-Maghrabi JA; Asa SL
    Saudi Med J; 2005 May; 26(5):728-31. PubMed ID: 15951858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism.
    Ozolins A; Narbuts Z; Vanags A; Simtniece Z; Visnevska Z; Akca A; Wirowski D; Gardovskis J; Strumfa I; Goretzki PE
    Langenbecks Arch Surg; 2016 Nov; 401(7):943-951. PubMed ID: 26658808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parafibromin as a tool for the diagnosis of parathyroid tumors.
    Marcocci C; Cetani F
    Adv Anat Pathol; 2008 May; 15(3):179; author reply 179-80. PubMed ID: 18434772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.